

RODA DE CONVERSA - AVALIAÇÃO EM SAÚDE

**COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN  
VERSUS TRASTUZUMAB EMTANSINE AS SECOND-LINE TREATMENT  
FOR HER2-POSITIVE METASTATIC BREAST CANCER IN BRAZIL.**

*Carlos Henrique Botelho (botelho13carlos@gmail.com)*

*Alessandro Gonçalves Campolina (alecampolina@gmail.com)*

*Maria Del Pilar Estevez Diz (maria.pilardiz@gmail.com)*

Adjuvant chemotherapy with trastuzumab, trastuzumab emtansine, and trastuzumab deruxtecan for HER2-positive metastatic breast cancer has evidenced benefits for disease-free survival and overall survival.

Given the high costs of these therapies and the budgetary constraints of the Brazilian public healthcare system (SUS), cost-effectiveness analyses are essential to guide treatment decisions.

Palavras-chave: economic evaluation; cost-effectiveness; cost-utility; her2-positive breast cancer; trastuzumab emtansine; trastuzumab deruxtecan.